Podcasts about Drug development

In December 2017, the FDA approved a new injectable drug to treat type 2 diabetes called semaglutide, which you likely know by its brand name: Ozempic. A few years later, during the pandemic, Wegovy, a drug with a higher dose of the same active ingredient, was approved specifically for chronic weight management. Soon after, people taking Ozempic started reporting a dramatic, even “life-changing” weight loss. Ozempic is now a bona fide blockbuster. So what's the science behind these “wonder drugs” that apparently 1 in 10 of us could end up using? They have the potential to have so many positive effects on our lives, from treating Alzheimer's disease and addiction to changing our relationship with consumption but, like with most things, they also come with risks.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode, Tania Simoncelli (Vice President, Translational Impact and Engagement, Chan Zuckerberg Initiative) and Nasha Fitter (Co-founder & CBO, Citizen Health and Co-founder & CEO, FOXG1 Research Foundation) join forces to discuss how rare disease patient advocacy has transformed over time and how the biopharmaceutical industry should adapt to better meet the needs of today's patients. They dive deeper into the evolution of rare disease patient advocacy groups, why industry must move beyond the hyperfocus on “blockbuster drugs” to make progress in rare disease research, and how advancements in rare disease treatments can benefit the clinical research ecosystem for all.

Analyzing Trump's plan to roll back soaring drug prices for Americans; Sports bras eliminate bounce but may take a toll on women's backs; RFK Jr. targets the chemicals in our food; Do Americans really eat more animal protein than any other of the world's nations? Causes and treatments for pulmonary hypertension.

On this episode of “Raise the Line” we welcome Dr. Sheldon Fields, a trailblazer in the nursing field and the president of the National Black Nurses Association. In a candid conversation, Dr. Fields shares his inspiring journey from the bedside to becoming a prominent figure in nursing, HIV/AIDS prevention and academia and also shares the challenges he faced as a Black man in a predominantly white and female field. "I fell in love with a profession that has not always loved me back," he tells host Kelsey Lafayette. Dr. Fields brings over thirty years of experience as an educator, researcher, clinician, administrator, consultant, health policy specialist, and entrepreneur to his current role at NBNA, and as the inaugural associate dean for equity and inclusion at the College of Nursing at Penn State University, where he also serves as a research professor. Listeners will find Dr. Fields' insights on navigating a career in healthcare particularly valuable, as he stresses the importance of resilience, continuing education, and mentorship. It's a compelling listen for anyone interested in the intersection of health, policy, and social justice.Mentioned in this episode:National Black Nurses Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Over the last 200 years or so, vaccines have come a long way, for a number of viruses. We've made so much progress, in fact, that in 2017 scientists began the early stages of vaccine development for some virus families they believed could pose a future pandemic threat. One of those families was Coronaviridae: coronaviruses. Not many people know that before SARS-CoV-2 started making its way into people in 2019, there was already a project underway in the U.S. to create a vaccine for a looming coronavirus (we didn't!), but even that would not have been possible without the decades of vaccine and drug research that came before it, particularly for HIV. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Link to the Tiny Show & Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Ayesha speaks with Norman Putzki, MD, Senior Vice President and Global Development Head of Neuroscience and Gene Therapy at Novartis, about the complexities and real-world challenges of bringing new therapies to patients with neurological diseases. Dr. Putzki discusses the challenges and opportunities in developing treatments for complex brain disorders, and how gene therapy is being applied in neurological disease. Dr. Putzki transitioned from an academic career in clinical neurology, with a focus on diseases like multiple sclerosis (MS), to the pharmaceutical industry in 2010. Since then, he has taken on leadership roles in both medical and development functions, first at Biogen and later at Novartis, where he currently leads global development efforts in neuroscience and gene therapy. During his tenure at Novartis, he has been leading teams around the globe to various new indications, approvals and launches within the neuroscience portfolio. Dr. Putzki received his PhD from Essen University in Germany and completed residency training in Internal Medicine and Neurology in Essen, University College London (Institute of Neurology Queen's Square) and University of Berne (Switzerland). Dr. Putzki is an author/co-author of more than 50 peer reviewed publications and has authored 4 books. He is a fellow of the American Academy of Neurology. Tune into the episode to learn more about the current landscape of drug development in neuroscience and neurological diseases — from research and strategy to execution on a global scale. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this episode, Logan is joined by Zach Weinberg (Co-Founder/CEO @ Curie.Bio) and Derek Thompson (writer at The Atlantic) for a candid discussion on the state of U.S. healthcare and scientific progress. They unpack what went right, and wrong, with COVID vaccine policy, the public backlash against mRNA technology, and the ripple effects on trust in science. The conversation also dives into the real reasons behind NIH budget cuts, the economics of drug discovery, and the business incentives in medical R&D. It's a sharp, thought-provoking look at the intersection of policy, innovation, and public perception. (00:00) Introduction to Drug Pricing in the US (00:23) Broad Healthcare Topics and Open-Ended Discussion (02:37) COVID-19 Vaccines: Successes and Public Perception (06:21) The Evolution of COVID-19 and Vaccine Efficacy (07:59) Public Policy and Vaccine Mandates (13:10) Impact of School Closures and Public Sentiment (19:23) NIH Funding and the Importance of Basic Research (25:04) Challenges in Science Funding and Public Perception (35:19) Government vs. Private Investment in Science (36:40) Operation Warp Speed: A Case Study (39:07) Antibiotic Resistance Crisis (43:22) The Drug Pricing Debate (44:05) Challenges in Drug Discovery (54:06) Regulatory Hurdles in Medical R&D (58:06) The Future of Drug Development (01:04:19) Concluding Thoughts Executive Producer: Rashad Assir Producer: Leah Clapper Mixing and editing: Justin Hrabovsky Check out Unsupervised Learning, Redpoint's AI Podcast: https://www.youtube.com/@UCUl-s_Vp-Kkk_XVyDylNwLA

Today's guest is Patricio La Rosa, Head of End-to-End Decision Science at Seed Production Innovation in Bayer Crop Science. With over 20 years of experience developing AI and data science solutions across healthcare and agriculture, Patricio joins Emerj Managing Editor Matthew DeMello to explore how machine learning can drive better outcomes across the drug development lifecycle, from research design to clinical deployment. Patricio discusses how AI is optimizing early trial planning, improving participant engagement, and supporting ethical, human-centered decisions at scale. Drawing lessons from both agriculture and life sciences, he emphasizes the importance of connecting technical models with real-world workflows. The conversation also delves into key barriers to AI adoption in clinical settings, including behavioral friction, model transparency, and challenges in orchestrating decision-making across global teams. Patricio offers a grounded perspective on what it takes to move from experimentation to enterprise impact in AI-driven R&D. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!

What does clinical trial monitoring have in common with growing a field of corn? Amy Kroeplin (PPD™ clinical research business of Thermo Fisher Scientific), Shailesh Madel (ICON plc), and Nicole Stansbury (Premier Research) join the podcast to discuss the importance of risk-based quality management, centralized monitoring, and strategic SDV/SDR sampling strategies. They dive deeper into the unique roles of SDV and SDR, different methods of implementing SDV/SDR sampling strategies, and the industry imperative to increase centralized monitoring adoption.

“Over 90% of people you meet in life sciences are going to be dealing with failure every day. You have to normalize failure in this industry to get the success you want,” says Beth Benatti Kennedy, discussing the unique pressures facing pharmaceutical professionals.Beth Benatti Kennedy brings more than two decades of experience as a leadership and resilience executive coach, working with major pharmaceutical companies including Takeda, Nautilus Biotechnology, and Pfizer. Beth is also the author of Career Recharge and co-author of ReThink ResilienceHer insights into preventing burnout have become increasingly relevant as the industry faces mounting pressures from accelerated development timelines and regulatory complexity. In this interview with PharmaSource, Beth shares critical strategies for building resilience.Read the full article

On this week's episode, Lisa Moneymaker (SVP, Head of Strategic Customer Engagement, Medidata Solutions) and Adam Aten (Legislative & Regulatory Policy Lead, Verily) join the podcast to discuss how the clinical research industry must use insights from the past to better prepare our AI models and other technologies to meet the needs of patients in the present and future. They dive deeper into the role that collaboration between technologists and clinical scientists can play in helping to reduce bias in our AI models, what legislators and regulators should be keeping top of mind as they write new rules of the road for AI and ML, and ACRO's ongoing efforts to promote the responsible use of AI in clinical research.

We're honored to continue our global tour of medical education today with Professor Katarzyna Taran, MD, PhD, a pioneering interdisciplinary researcher of tumor cell biology, an award winning educator noted for her focus on student engagement, and -- in a first for a Raise the Line guest -- a shooting sports certified coach and referee. As Professor Taran explains to host Michael Carrese, these seemingly disparate professional activities require the same underlying attributes: patience, the ability to overcome barriers, openness and adaptation. She believes those last qualities are especially important for today's medical students to acquire given the accelerated pace of change in healthcare. “They need to be equipped with the ability for critical thinking, to analyze and synthesize, and to search for unconventional solutions.” Professor Taran tries to impart these skills, in addition to the medical and scientific knowledge students must know, through a high level of engagement. “Teaching is relational, so try to be familiar with students' concerns. Talk to them, listen to them and you will become someone they trust.” In this wide-ranging and engaging conversation, Professor Taran also discusses her work as the head of the Laboratory of Isotopic Fractionation in Pathological Processes in Chair of Oncology, the use of neurodidactics in teaching, and the connection between the science of pathology and the future of humans in space. Mentioned in this episode:Medical University of Lodz If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about how the real hurdle in clinical research lies in effectively integrating AI. Stelzer discusses the need for greater coordination within the pharmaceutical industry, particularly between life sciences and software engineering and explains how bridging the cultural divide can significantly enhance the adoption of emerging technologies like AI. Of course, the conversation also touches upon the importance of collaboration, which can positively empower pharmaceutical companies to overcome existing challenges and drive significant advancements in drug development. You can listen to episode 176a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

On this week's episode, host Sophia McLeod is joined by Danilo Branco (Associate Director, Risk Based Quality Management Lead, BeOne Medicines) and Amanda Coogan (Associate Director, Customer Experience, Remarque Systems) to discuss the value of centralized monitoring implementation by sharing case studies from today's clinical trials. They dive deeper into how centralized monitoring can help detect adverse events more quickly and identify underreporting, the benefits of holistically monitoring trial data using centralized monitoring, and how a targeted SDV/SDR sampling strategy can help organizations to conserve resources while maintaining quality and safety.

In the latest episode of Let's Talk Rare, Owen Bryant & Georgie Rack delve into the world of drug development in rare diseases.They are joined by the brilliant Rob Freishtat, president of Uncommon Cures. Rob brings unique insights on who the key stakeholder are in developing drugs and the many ways that we can bring them together in order to improve and enhance the delivery of much-needed therapies.

00:00:00 Surf's Up, Season 6, Episode 6.On April 23, 2024, our colleague and co-founder, Stephen Harrison, passed away suddenly. This week, Surfing the MASH Tsunami remembers Stephen with two of his closest associates and continues our annual MASH Drug Development roundtable held in his honor. 00:00:04:24 - A Deep Dive into Drug Development, Part 2The second portion of the Drug Development roundtable primarily focuses on three key issues. The first, uptake of resmetirom, starts with Naim Alkhouri discussing his experience in the Arizona Liver Health Clinics with over 650 patients in the year since resmetirom was approved and shifts to the various European panelists (Jörn Schattenberg, Louise Campbell and Sven Francque) estimating when it might be approved in their countries and how widely it might be reimbursed.  The second topic, incretin agonists, focuses on exciting prospects for other incretin agonists in development, as well as some semaglutide combination therapies. The third, NIT clinical trials, covers prospects that non-biopsy clinical trials might be approved sometime in the near future.00:16:20 - Remembering Stephen Harrison I: An Interview with Summit Clinical Research CEO Gail HinksonSummit CEO Gail Hinkson joins Roger Green for the first time on SurfingMASH to discuss her business partner. Gail discusses how the two originally formed Pinnacle Clinical Research and how Pinnacle led to Summit. She proceeds to discuss the current size and reach of both Pinnacle and Summit. Focusing on Summit, Gail describes the company as an Integrated Research Organization (IRO), highlighting its distinct role within the MASH firmament. In the final section of the interview, Gail discusses how Stephen's personality, goals, and vision continue to live on at Summit today.00:34:31 - Remembering Stephen Harrison II: An Interview with Naim Alkhouri Announcing That He Is Joining SummitNewly announced Summit Chief Academic Officer Naim Alkhouri joins this episode for a second time, but in a very different role. Naim discusses his personal history with Stephen and what he loved and respected about his "dear friend." He then makes a major announcement: he is joining Summit as Chief Academic Officer. He shares the many elements of this role, particularly his excitement that Summit can become the entity that educates a wide range of healthcare and commercial professionals on what MASH is and how it is treated. The scope of this vision, combined with what Gail discussed, portrays a level of energy, ambition and vision worthy of Stephen Harrison.00:55:55 - ConclusionAs part of this memorial week, Roger Green forgoes the usual business report, which will return next week.

ACRO's Good Clinical Podcast is back for season 3! To kick off the season, host Sophia McLeod is joined by Clare Campbell-Cooper (Global Head, Digital Health and Innovation, Fortrea) and Michael J. Cohen (Sr. Director, Lead, Environmental Sustainability, PPD™ clinical research business of Thermo Fisher Scientific) to discuss the continued evolution of environmental sustainability in clinical research. They dive deeper into how the clinical research industry can use renewable energy to help meet environmental goals, the importance of promoting more environmentally sustainable shipping and logistics practices, and how our industry can decentralize trial elements responsibly to minimize the environmental impact of the clinical supply chain.

This conversation is the opening segment of SurfingMASH's April discussion, in memory of Stephen A. Harrison, on drug development. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. This opening discussion focuses on exciting advances in one drug class (FGF-21s) and, more broadly, on exploring ways to treat cirrhosis. As Naim points out in his opening comment, these two issues— cirrhosis as a challenge and FGF-21s as a possible solution path —intersect in clear and exciting ways. He notes that the FGF-21 efruxifermin has been reported to have significant improvement in patients with cirrhosis, while the FGF-21 pegozafermin has shared positive results in a small cohort of patients. He also notes that a third FGF-21, efimosfermin alfa, has results in advanced non-cirrhotic MASH that suggest potential for similar efficacy in patients with cirrhosis, but this must be studied and confirmed in clinical trials. He mentions that resmetirom may also be showing signs of efficacy in some patients with cirrhosis. The entire package, he says, is a "game changer."Jörn notes that we are having parallel advances in treatment for advanced, non-cirrhotic patients. Sven concurs and comments that we are seeing effects that are not strictly related to metabolic disease. There is exceptional power that we can demonstrate one-level regression in sicker patients. The three agree that, at the same time, we are seeing cirrhosis trials that will lead to outcomes data; outcomes trials in non-cirrhotic medications may not be far away.Roger asks whether we are making progress in treating patients living with decompensated cirrhosis. Sven discusses what we are learning about treating portal hypertension, which is an important benefit unrelated to fibrosis regression. Simply improving portal hypertension will have an impact on endpoints. Naim points out that some ongoing trials include patients with cirrhosis, including survodutide and belapectin. Louise notes it will require "great P.R." to reverse some of the current perceptions about cirrhosis, but that this is "great." Naim states that even today, we have "a lot to offer" patients with portal hypertension or other symptoms of decompensation. As he concludes, he notes that this is underappreciated today. 

Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China

00:00:00 - Surf's Up: Season 6 Episode 5Host Roger Green briefly describes this episode's three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:10:39 - Roundtable: A Deep Dive Into Drug Development, Part OneThe opening portion of this month's roundtable centers around two issues: exciting data for FGF-21s and, more generally, treating patients with cirrhosis. Naim Alkhouri sets the tone in his opening comments, which start by focusing on the exciting SYMMETRY data from efruxifermin and then hones in on FGF-21s and resmetirom in cirrhosis. The rest of the conversation features Jörh Schattenberg, Sven Francque and Naim discussing therapies in development for compensated and decompensating cirrhosis.00;24:44 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing ResmetiromNaga joins Roger to discuss the paper Early Experience with resmetirom to treat Metabolic Dysfunction-Associated Steatohepatitis With Fibrosis in a Real-World Setting from his group at Indiana University, which his group authored and Hepatology Communications recently posted. The paper, based on IU Health's experience with its first 113 resmetirom patients, shares the group's practical experience developing processes to work closely with the specialty pharmacies dispensing resmetirom and, finally, concludes that a more engaged patient management strategy might reduce drug discontinuation to a level comparable with clinical trials.  00:47:21 - Expert: Scott Friedman on Gene Therapy, Diversity of Stellate Cell Types, Other Basic Liver ScienceScott and Roger cover a range of basis science topics in a fast-moving 19-minute discussion. It starts with Scott discussing the increasing acceptance that gene therapy is an acceptable way to treat a range of liver diseases, many of which are orphan or ultra-orphan but, in fact, include potential gene therapies for non-cirrhotic MASH and MASH cirrhosis. He notes that in addition to classic gene therapy, which introduces protective gene variants into the systems of patients with the risky variants, gene therapy is now looking to introduce FGF-21 into patients through genetic modification. From there, the conversation covers CAR-T therapy, the increasing ability to identify many different types of stellate cells and the idea that the most effective therapy for eary fibrosis, advanced fibrosis and cirrhosis might require fundamentally different kinds of interventions. The two final elements are the idea that what we now call "MASH" may be several diseases with different etiologies with similar manifestations and a passionate call for all of us to support maintaining NIH funding in whatever ways we can.01:06:45 - Business ReportAs Roger copes with his laryngitis, AI voices deliver an abbreviated business report 

We like to think of Osmosis from Elsevier as a global community of millions of learners, connected by a desire to serve humanity and an inclination to use a diverse mix of educational resources to help them become excellent healthcare practitioners. On today's episode of Raise the Line, we're going to learn how Osmosis has created an opportunity for hundreds of those students from sixty countries to actually solidify those connections through the Osmosis Health Leadership Initiative (OHLI). Our guide to this effort is Osmosis Community Specialist Alfred Collins, who brings a keen interest in developing tech solutions to power the future of human communication to his work with OHLI.“Technology collapses barriers to communication and to understanding the nuances behind culture, behind global perspectives,” he tells host Lindsey Smith. One example he cites is how OHLI members learn about variations in the way different cultures approach collaboration, an important insight to gain as they head into team-based healthcare environments. OHLI members convene regularly over video sessions to hear from leaders in healthcare and learn about hosting successful on-campus events, among other enriching content.  They also have an opportunity to provide feedback on improving the Osmosis learning platform, and this year they're participating in a “hackathon” aimed at improving the future of healthcare. Tune in to find out more about what the OHLI program offers, how to apply, and how Alfred thinks virtual reality and AI technologies will impact the future of community building. Mentioned in this episode:Osmosis Health Leadership Initiative If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

The Future of AI in Pharma & Biotech Research #aiinbiotech #pharmaresearch #drugdiscovery AI is fundamentally changing the way biotech and pharmaceutical research happens. From analyzing vast datasets to accelerating drug discovery, AI-powered solutions are making labs smarter, faster, and more efficient. But how does it actually work? Please visit our website to get more information: https://swangroup.net/ In this episode, I sit with Liran Belenzon, CEO of BenchSci, to explore how AI reshapes pharmaceutical research. We discuss:✅ The biggest challenges of working with scientific data✅ Why big pharma companies prefer AI-powered platforms over in-house solutions✅ How multimodal AI enhances lab efficiency and accelerates drug developmentLiran also shares his journey from being an MBA student to leading a company that works with 12 of the world's top 20 pharma companies. If you're curious about the intersection of AI, biotech, and research, this episode is a must-watch. Let's talk about the future of AI in biotech. What excites you the most? Let me know in the comments. Links from this episode:✅ Get to know more about Liran Belenzon: https://www.linkedin.com/in/liranbelenzon ✅ Learn more about BenchSci: https://www.benchsci.com ✅ Follow BenchSci for updates on AI in biotech: https://ca.linkedin.com/company/benchsci 

Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.

This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He points to efruxifermin's 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug's duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin's publication of data in the New England Journal of Medicine and efimosfermin's promising data based on monthly dosing. Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies. 

00:00:00 - Surf's Up: Season 6 Episode 4 Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners. Our newsmaker, Fatty Liver Alliance and CEO Mike Betel, discusses the lessons he has taken from being invited to a far wider swath of conferences this year and shares the messages he delivers to these new audiences. Finally, our expert, hepatology research and key opinion leader Mazen Noureddin, discusses recent advances in drug development, focusing on agents in Phase 3 trials.00:04:24 - IntroductionHost Roger Green briefly describes this episode's three sections and one key lesson from each.00:06:03 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 4This is the concluding portion of our Emerging Trends Conference Roundtable. The group focuses on key lessons they have learned and messages they would like listeners to take from this conversation.  The pivotal idea is that SLD is a spectrum running from MASLD through MetALD to ALD. Researchers and treaters will all do best in developing and implementing therapies and guidelines with this thought in mind. Aleksander Krag stresses this idea and notes that, with several different classes of drugs demonstrating positive impact, it will be an exciting decade ahead as we learn how to apply these drugs along the spectrum. Jenn Jones and Alex Lalos note the importance of identifying MetALD, although Jenn noted that it does not seem wise to conduct trials solely with MetALD patients at this time.  00:22:04 - Newsmaker: Mike Betel on the Increased Visibility of Patient AdvocatesThis week's newsmaker, Mike Betel, has experienced a significant increase in the number of conferences at which he is invited to speak or appear on a panel. This discussion centers around the reasons Mike believes this is happening and the message(s) he delivers. To Mike, his most important contribution lies in the amount of information he sends back from each event, many of which surpass 30% download rates (and some even hit 50%). He discusses his value in diabetes, endocrinology and obesity meetings, where he brings a "liver" perspective and co-education opportunity to these events. The entire experience has taught him about the need not to stigmatize patients and reinforced his belief in the importance of tailoring care to patients' needs and personalities. 00:49:28 - Expert: Mazen Noureddin on the Exciting MASLD Drug Development EnvironmentHepatologist and Key Opinion Leader Mazen Noureddin joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. Specifically, he discusses the FGF-21 agents, the range of patients for whom they might be appropriate, how efruxifermin's 96-week results may make the idea of "induction therapy" less appropriate,  and the exciting early data on cirrhosis patients. He provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. He goes on to discuss the pan-PPAR lanifibranor, the FASN inhibitor denifenstat, and notes ongoing work on new classes and combination therapies. In general, he paints, I think, not a rosy, but an extremely optimistic picture of what the future will be for patients who need to be treated for fatty liver. 01:09:38 - Business Report Roger discusses the next Roundtable and provides some details on SurfingMASH's coverage of the upcoming EASL Congress.

Send us a textOn this Monday Morning Minute, Dr. Michael Koren draws parallels between the NCAA Final Four basketball tournament and the clinical research process. He explains that in medicine, researchers start with literally 10,000 potential molecules, which get whittled down to only three or four medications to be tested in big, phase III clinical trials. This ensures that only the most promising medical technologies get approved, just like the most promising teams get to the National Championships.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

David Game remembers the days when the use of digital technology in education publishing amounted to putting a dictionary on a compact disc. Now, as the senior vice president of Product Management, Global Medical Education at Elsevier, he oversees a suite of learning materials that use artificial intelligence, virtual reality and 3-D modeling. “We've expanded into immersive technology with Apple Vision Pro that enables you to be inside the human body, to see and explore the human heart from the inside out and it is absolutely stunning,” says Game, whose long career in publishing includes experience in North America, the United Kingdom, Europe, China and India. As Game has witnessed first-hand, advancements in ed tech, including distance learning, have provided students with an array of options and modalities to choose from that accommodate different learning styles and life circumstances, and that puts a premium on being able to meet students where they are. “We want to make sure that students find learning from our materials engaging, efficient, and aligned with how they live their lives and do their work.” Join host Lindsey Smith for this fascinating episode of Raise the Line to learn how Elsevier is leveraging the innovations offered by Osmosis, Complete Anatomy and ClinicalKey Student to enrich the learning of medical students on their journey to becoming excellent clinicians.Mentioned in this Episode:Complete AnatomyClinicalKey StudentOsmosis If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

In this episode, I talked to Dr. Karolina Valente, CEO of Voxcell BioInnovation. Dr. Valente talks about how her company, Voxcell, is trying to revolutionize the drug development process by developing customizable 3D tissue models to test different therapeutics and drugs. We also talked about how AI will affect future drug trials, Vancouver's potential as a biotech hub, improvements needed to strengthen Canada's biotech industry, Voxcell's new and old products, and the difficulty of raising money to go to different rounds. ---------------------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoatNewsly: https://newsly.mepromo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.compromo code: DG Dubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips:  https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c  Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.com

“We didn’t start Model to launch a company — we started it because no one else met our standards,” says Dr. Daniel Haders II, CEO and founder of Model Medicines. On this episode of Vanguards of Health Care, Haders speaks with Bloomberg Intelligence analyst Andrew Galler about building an AI-native drug discovery engine capable of identifying cryptic binding pockets and designing first-in-class drugs. They unpack why hit rates and novelty must go hand-in-hand, an overview of the company’s pan-antiviral MDL-001, and why generalizability — not reinforcement learning — is the true litmus test for AI in biotech.See omnystudio.com/listener for privacy information.

How can pharmaceutical companies best navigate setbacks in drug development to deliver breakthroughs in R&D? Find out in this week's episode, where Isabel and Jade share an interview with Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim.  Together, he and Jade explore the ins and outs of drug failure, whether to pivot or persevere after an R&D setback, how to better break the stigma of mental illness and much more.  A little more on EMJ GOLD's guest…  Christoph von der Goltz is Global Head of Medicine Central Nervous System and Emerging Areas at Boehringer Ingelheim. He has more than 15 years of experience in a variety of roles in pharmaceutical R&D. He is also a board-certified psychiatrist with more than 10 years of clinical experience in neurology and psychiatry and academic research in preclinical, clinical and public health projects in Germany and Sweden. 

Isomorphic Labs raised $600 million in its initial external funding round to enhance artificial intelligence applications in drug development. Thrive Capital led this round, supported by Google Ventures and existing investor Alphabet. Isomorphic Labs, formed from Google DeepMind in 2021, aims to advance its AI drug design engine and clinical programs. This funding follows significant raises in the AI-driven biotech sector, including Xaira Therapeutics, which secured $1 billion, and Formation Bio, which raised $372 million. Thrive Capital, co-founded by Joshua Kushner, has also led major investments in Databricks and OpenAI.Learn more on this news visit us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

Gábor Somlyai, PhD is a Hungarian molecular biologist and world expert in the role of deuterium in cancer. He has published seminal work looking at the effects of various concentrations of this heavy isotope of hydrogen on growth and metastasis. Gábor's company, HYD LLC. for Cancer Research and Drug Development, has been at the forefront of developing deuterium depletion protocols as a synergistic cancer therapy. Their work over the last 30+ years has demonstrated the profound potential of deuterium depletion in not only cancer, but other disorders including type 2 diabetes. The identification of this submolecular regulatory system shaped by the relative abundance of deuterium to hydrogen in the body provides a framework with which we can further understand what cancer is and how sensitive our bodies are to subtle environmental information.All elements on the periodic table have isotopes - slightly different configurations of the same atoms that have slightly different chemical characteristics. Hydrogen is the simplest atom, with one proton, and one electron. But hydrogen also has another stable isotope called deuterium, with one proton, one electron and one neutron. This is still hydrogen, but it is double the atomic weight and consequently behaves differently. In our bodies, approximately 1 out of every 6600 hydrogen atoms (also referred to as 150ppm) is a deuterium atom. Our cells are exquisitely tuned to this deuterium/hydrogen ratio, and they use this ratio as a foundational signal in cell division. As deuterium levels shift, large scale changes in bioenergetics and genetic expression result. Gábor's work shows that lowering the deuterium level can effectively inhibit the growth of cancer cells.Gábor's WorkBook: Defeating Cancer: A New Way In Curing Cancer & Preserving HealthPreprintPreventa Deuterium Depleted WaterPublicationsHYD LLC. for Cancer Research and Drug DevelopmentFollow MeWebsiteSubstackConsultationInstagramYoutubeTwitter/XSpotifyAppleLinktree

Welcome to Research Renaissance, presented by the Karen Toffler Charitable Trust. In this episode, host Deborah Westphal sits down with Dr. Kasper Roet, CEO and co-founder of QurAlis, to explore the evolution of ALS drug development, the power of genetic insights, and the future of personalized medicine for neurodegenerative diseases.

An interesting new study from the Geisinger health system in Pennsylvania examining if genomic screening in a large population increases the identification of disease risk prompted Raise the Line to re-release a previous episode about a textbook designed to help all medical providers understand the clinical applications of genomic testing. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counseling from Elsevier Science Direct dives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases. Mentioned in this episode: Genomics in the Clinic: A Practical Guide If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

International markets have outperformed the U.S. in a big way this year, but will the trend continue into Q2? Where are out traders see the biggest global gains, and if they're betting on more divergence between the markets. Plus NIH funding cuts putting drug development on the chopping block. The names feeling the impact, and what's at stake in the pharma space.Fast Money Disclaimer

In this episode, Harriet Edwards from Boyds hosts a discussion on 2025 predictions in drug development and regulatory affairs. Joined by regulatory experts Dr. Katherine Bowen and Dr. Eric Harder, the conversation covers the anticipated trends in the realm of cell and gene therapy, rare diseases, and the increasing role of artificial intelligence (AI). As we look ahead to 2025, Boyds' regulatory experts discuss the evolving regulatory landscape, legislative changes in the US and EU, and the importance of patient-centric approaches. Join us for this insightful journey as we uncover what 2025 has in store for drug development and regulatory strategies. 

Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do?In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis' unique system which combines laser printed human organoids and an externalized human immune system with AI, enabling the discovery of fully human antibodies. If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits.Links:Explore Prellis Biologicshttps://prellisbio.com/Understand AlphaFold, DeepMind's AI model for predicting protein structureshttps://deepmind.google/alphafoldRead about the 2024 Nobel Prize in Chemistry https://www.nobelprize.org/prizes/chemistry/2024/press-release/ 

Dr. Tania Small joined Bristol Myers Squibb as Senior Vice President, Global Medical Affairs in January 2024. Tania brings a strong scientific track record leading Medical Affairs teams in driving innovation that improves the experience and supports better outcomes of people living with cancer and rare diseases. She has successfully built and led global and regional medical organizations in Drug Development and Medical Affairs, advancing access to Oncology, Rare Disease and Hematology patients globally.Tania is a board-certified pediatric hematology, oncology, and bone marrow transplant specialist with deep experience in clinical research and drug development. She has extensive research experience in oncology, hematology, gene therapy and stem cell transplantation, receiving NIH grants for her translational research in gene therapy and regenerative medicine.Most recently, Tania served as Head of Global Medical Oncology and was the sponsor of the Global R&D Inclusion Diversity Council at GSK. Prior to GSK, Tania worked for IPSEN as Vice President, Head of Oncology and Rare Disease Global Drug Development.She is energized by revolutionizing the experience and outcomes for people with cancer, and has worked closely with the US FDA, Congress, and the American Society of Clinical Oncology (ASCO) to improve the diversity of enrollment in oncology clinical trials and elderly programs."I'm passionate about partnering to create programs that treat the person - not just the disease. Producing groundbreaking solutions that can change the trajectory of serious diseases and help write the next chapter of patient-driven science is what motivates me every day."Tania received her medical degree from Albert Einstein College of Medicine. She has a long-standing affiliation with the Morgan Stanley Children's Hospital of New York Presbyterian/Columbia University where she completed her residency and hematology/oncology fellowship with an academic research appointment in heme and bone marrow transplant.Currently, Tania serves on the ASCO Membership Advisory Committee and is a Board Member of Accreditation Council for Medical Affairs (ACMA).

On this special episode of ACRO's Good Clinical Podcast, 2025 ACRO Chair Jim Reilly (Veeva) and Vice-Chair Sandy Kennedy (Fortrea) join the podcast to discuss the current state of the clinical research ecosystem and where our industry should focus attention to continue moving research forward in 2025.They dive deeper into the challenges and opportunities in making clinical research more accessible globally, the benefits of standardization in research, how our industry relationship with sites must evolve, and the positive impact that more representative trials have on data quality.

The agrochemical field has long relied on animal models to evaluate the safety and efficacy of substances, but there's a growing demand to adopt new alternative methods (NAMs) that can further the industry while reducing the need for animal testing. However, questions remain as to their long-term viability.   Join Robert Landsiedel, Vice President of Experimental Toxicology and Ecology, and Susanne Kolle, Research Coordinator of Experimental Toxicology and Ecology at BASF, as they explain the benefits of NAMs, how they comply with the 3Rs principle, and the role collaboration is playing to push NAMs as a viable alternative to animals.Show Notes     Alternative Methods  AMAP Strategic Partnerships Animals in Research  Modernizing Drug Development Agrochemical Testing Service for Approvals Chemical Testing Services Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals Charles River Laboratories, in Collaboration with MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives

To mark International Rare Disease Day, we're going to introduce you to a remarkable young woman, Zainab Alani, who is not letting her challenging rare condition stand in the way of her dream of becoming a physician. After noticing Zainab's struggles with muscle weakness and fatigue at age 15, her mother – a physician – took her to doctors advocating for a diagnosis of the rare autoimmune condition generalized myasthenia gravis (MG). Unfortunately, a series of clinicians attributed her symptoms to her menstrual cycle and other errant causes and even accused Zainab of being ‘a lazy teenager.' “Despite having that support and knowledge behind me, these doctors were dismissing my symptoms because of that deceiving label of rare,” Zainab explains to host Lindsey Smith. Wanting to spare others from this frustrating diagnostic odyssey, Zainab turned to advocacy once in medical school and is working with her sister and others through the organization Rare Aware Glasgow to raise awareness among the general public about rare conditions and to spur the medical community to adjust its perspective. “We don't expect medical professionals to know every single rare disease, we just want them to acknowledge their existence and not dismiss them when a family member or a patient brings them up as a differential diagnosis.” In this inspiring episode in our Year of the Zebra podcast series you'll also learn about intersectionality creating burdens in medical diagnosis and a questionable basis for patients being denied access to new treatments.Mentioned in this episode:Rare Aware GlasgowThe Myasthenia Medic If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

In February, the Inside the ICE House Podcasts aired four new episodes covering a diverse range of industries, from the development of ICE Voice and the changing workforce, to the rebranding of an insurance industry icon and how AI is helping in drug development. Episode 456: IPC Systems CEO Kurt Adams on Innovation, Acquisition, & the Development of ICE Voice Episode 457: Author Rishad Tobaccowala on Retraining, Relearning, and "Rethinking Work" Episode 458: Novartis CEO Vas Narasimhan on Drug Development & AI's Role in Disease Treatment Episode 459: The Hartford's Chris Swift & Claire Burns on Legacy, A Bold New Look, and Lasting Impact

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com The crucial combination of human expertise and AI is paramount for success in drug development.  In this episode, Liesbeth Ceelen, CEO, and Arjan van Manen, Commercial Director of BioLizard, discuss the critical role of data analytics and machine learning in the pharmaceutical industry, highlighting the increasing need for companies to become data-driven. They emphasize how a deep understanding of biology, supported by AI, can optimize target discovery and reduce clinical trial failures. BioLizard offers the expertise and a platform to support biotech and pharma companies in this new data-driven approach as the industry shifts from viewing data analysis as a cost to a necessity for better outcomes. Finally, they touch upon predictions for 2025, focusing on a more data-supported approach to drug development, tailored treatments, and a heightened focus on target mechanisms while remaining optimistic about the changing mindset of industry stakeholders. Tune in and learn how data analytics can transform your approach to drug development! Resources:  Connect and follow Liesbeth Ceelen on LinkedIn. Follow and connect with Arjan van Manen on LinkedIn. Follow BioLizard on LinkedIn and visit their website. Discover more about BioLizard's platform, BioVerse, here. Fast Track Your Business Growth: Outcomes Rocket is a full service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com

(2:30) - AI-designed proteins neutralise snake toxinsThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn more about how AI is being used to expedite the drug development discovery phase! Hint: it's a great primer for this episode :) Become a founding reader of our newsletter: http://read.thenextbyte.com/ As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.

Having the ability to manage uncertainty is helpful in all professions, but perhaps especially so in medicine where uncertainty abounds and the stakes for managing it are high. Despite that, medical students receive little training in this area, something which our guest today, Dr. Jenny Moffett of RCSI University of Medicine and Health Sciences in Dublin, is working to change. “There are approaches to uncertainty that can be learned. We can change our perspective and perceptions around uncertainty, stepping away from always viewing it as something aversive, but perhaps maybe looking at it with a little bit more curiosity and openness, and that's definitely a transformation that faculty can make,” says Dr. Moffett, the program director of the Postgraduate Diploma in Health Professions Education. In addition to a perspective shift, Moffett also believes providers should develop skills to talk about uncertainty with patients in an open and honest way. “Clinicians can say, I'm on this journey with you. I don't have all of the answers, but we have paths, we have options, and I'll be there with you as we work them out.” Join host Caleb Furnas as he explores Dr. Moffett's fascinating work in this area which includes development of an immersive puzzle game that encourages students to address complex, ambiguous, and unpredictable issues.Mentioned in this episode:RCSI University of Medicine and Health Sciences If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

We know this has happened to you. You go to pick up a prescription and are floored by the price. Or even worse, you have had a loved one diagnosed with a rare disease only to find limited treatment options.   The pharmaceutical industry needs drastic change, and Dr. Jo Varshney is all in on making that happen. As Founder and CEO, VeriSIM Life, Jo leads a team of world-class scientists, machine learning engineers, and in silico simulation experts bringing clarity to drug development through computational sciences rather than the existing trial-and-error experimentation approach. However, intelligence and knowledge aside, Jo is a business leader on a mission and one of the most enjoyable founders I have had the pleasure of speaking with to date.   If you listen to this episode you will hear us touch on: VeriSIM Life's Mission: The company uses "hybrid AI" to create simulations of human and animal biology to speed up drug development, producing a "translational index" that predicts clinical risks and mitigates them, akin to a credit score for drugs.   Team Dynamics: Jo emphasizes the importance of having a dedicated, collaborative, and ambitious team at VeriSIM Life. She explains finding the unique formula for building their culture and that she values employees who have a "chip on their shoulder" and want to prove themselves and drive the mission while avoiding "genius jerks" who lack humility and empathy.   AI and Biology: Jo discusses the hype surrounding AI and the need for realistic expectations. VeriSIM Life focuses on appreciating the complexity of biology and combining AI with mathematical and knowledge systems to improve accuracy and reduce biases. She shares how they identified a new drug for pulmonary hypertension and how with VeriSIM's tools they greatly reduced costs and timelines.   Advice to New Founders: Jo differentiates between "missionary" and "mercenary" founders, advising them to stay passionate but separate themselves from the stories of rejection and challenges.   Continuous Learning: Jo recommends the book "Courage to be Disliked," which resonated with her deeply, reflecting her belief in the importance of being true to oneself and not being deterred by others' opinions.   About the guest: Dr. Jo Varshney was born to a pharmacological pedigree in India. Being introduced to the world of drug development and research at a young age, and an ethic of competitive achievement, she developed a passion and understanding for science and technology much earlier than most.   Today, Varshney is the Founder and CEO of VeriSIM Life, and the inventor of VeriSIM Life's BIOiSIM core technology. A virtual drug development engine that harnesses the power of traditional statistical modeling along with artificial intelligence and machine learning, BIOiSIM enables pharma and biotech professionals to bring more lifesaving and cost-efficient therapies to patients faster than ever before.   Over the past several years, Dr. Varshney has front-led numerous collaborative engagements with a host of pharmaceutical clients, government agencies, academic/medical institutes and industry innovators. She is a dynamic and celebrated leader and has received numerous accolades as well as delivered keynotes at several conferences.   Connect with Jo: Website: www.verisimlife.com LinkedIn: https://www.linkedin.com/in/jyotika-jo-varshney/   Connect with Allison: Feedspot has named Disruptive CEO Nation as one of the Top 25 CEO Podcasts on the web and it is ranked the number 10 CEO podcast to listen to in 2024! https://podcasts.feedspot.com/ceo_podcasts/ LinkedIn: https://www.linkedin.com/in/allisonsummerschicago/ Website: https://www.disruptiveceonation.com/ Twitter: @DisruptiveCEO    #CEO #brand #startup #startupstory #founder #business #businesspodcast #podcast  Learn more about your ad choices. Visit megaphone.fm/adchoices

The pharmaceutical industry is experiencing extraordinary innovation, fueled by breakthroughs in science, technology, and data analytics. Novartis (NYSE: NVS) stands as a driving force in this wave of transformation. From gene and cell therapies to targeted cancer treatments and immunology, Novartis consistently delivers solutions for some of the most complex health problems. CEO Vas Narasimhan goes Inside the ICE House to discuss the significant success achieved and how the company, under his leadership, sharpened its focus on innovative medicines to combat some of the world's most pressing medical challenges. https://www.ice.com/insights/conversations/inside-the-ice-house

The Role of Clinicians in Addressing Climate Change: Dr. Catharina Giudice, Climate and Human Health Fellow, Harvard T.H. Chan School of Public Health “The healthcare system is in this interesting intersection when it comes to its roles and responsibilities as it pertains to climate change,” says our Raise the Line guest Dr. Catharina Giudice, a research fellow in climate and human health at Harvard University.  As she explains to host Hillary Acer, the medical industry is a major producer of the greenhouse gasses that are contributing to serious health impacts on patients, especially those who are already vulnerable due to pre-existing conditions and economic struggles. Giudice, whose academic work focuses on healthcare sector climate preparedness, believes this paradox requires a response from clinicians. “There's so many small things that you can do as an individual clinician to make a difference in the climate change intersection.” Options include working to change hospital practices, educating peers and patients on the health impacts of climate change, and advocacy in the public policy arena. In this thought-provoking installment in our NextGen Journeys series, you'll also learn how the healthcare delivery system is being affected by climate change, and about a new concentration in climate change and planetary health at the Harvard T.H. Chan School of Public Health.Mentioned in this episode:Harvard T.H. Chan School of Public HealthHarvard University Center for the EnvironmentPractice Greenhealth If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

In this episode of The Harry Glorikian Show, host Harry Glorikian welcomes back Jeff Elton, CEO of Concert AI, to discuss the latest advancements in AI-driven healthcare solutions. They reflect on the recent JP Morgan Healthcare Conference, highlighting the optimism surrounding AI's role in transforming drug development and oncology. Jeff shares insights into Concert AI's innovative data ecosystems, partnerships, and the introduction of Kera, an AI platform designed to enhance clinical decision-making. The conversation also explores the challenges and opportunities in the evolving landscape of healthcare technology, emphasizing the importance of collaboration and adaptability in the face of rapid change.Takeaways:The JP Morgan Healthcare Conference indicated a positive outlook for the industry.AI is becoming a central theme in healthcare discussions.Concert AI is developing a comprehensive data ecosystem for oncology.The introduction of agentic AI models is set to revolutionize data processing.Collaboration with NVIDIA is enhancing Concert AI's capabilities.Kera is a significant advancement in AI-driven healthcare solutions.The future of drug development will rely heavily on AI and data analytics.Healthcare organizations must adapt to the rapid pace of technological change.Building partnerships is crucial for addressing healthcare fragmentation.The integration of AI in clinical trials can significantly reduce timelines.Chapters 00:00 The Annual Healthcare Pilgrimage03:19 Optimism in the Pharma Industry06:07 The Rise of AI in Healthcare10:03 Concert AI's Evolution and Innovations15:10 2024: A Standout Year for Concert AI18:55 Balancing Growth and Innovation22:33 Scaling Across Therapeutic Areas26:26 The Future of Collaborations in Healthcare28:37 Integrating Immune Status and Data Collaboration31:04 Introducing Kera AI: The Future of Data Management35:24 Innovations in Clinical Trials and Data Solutions40:16 Rethinking Drug Development: Digital Twins and AI42:36 Navigating Market Shifts and Talent Challenges54:02 The Future of Concert AI and Healthcare Solutions  

We continue our NextGen Journeys series today featuring fresh perspectives on education, medicine, and the future of health care with an impressive medical student who was brought to our attention by a previous podcast guest, Dr. Michael Foti, whom we'd like to thank for the recommendation. Nikolas Bletnitsky is in his third year at Touro College of Osteopathic Medicine, Middletown, but that's just one element in his medical education. Over the last several years, Nick has done extensive work in the field of OB-GYN -- completing clinical electives in Paris, France and Bologna, Italy, in addition to the Mayo Clinic -- where he has pursued his intense interest in a variety of subspecialties, including maternal fetal medicine. “Right now I'm doing a lot because I'm young and I have the energy and I want to see a lot to give me different perspectives on things so that I can incorporate them into my own practice,” he tells host Michael Carrese. Join us for a wide-ranging conversation in which you'll learn about current practice in OB-GYN in the US and Europe, neonatal palliative care and advances in fetal surgery, along with what Nick has learned about having crucial conversations with the parents of patients when tough news needs to be discussed.Mentioned in this episode: Touro College of Osteopathic Medicine, If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast